Editas Medicine (EDIT) Stock: Buy, Sell, or Hold?
EDIT - Editas Medicine, Inc. Common Stock
$2.51
-0.07 (-2.71%)
▼
5d:
+10.57%
30d:
-14.04%
90d:
-8.06%
HOLD
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 09, 2026
17d
Get Alerted When EDIT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EDIT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: EDIT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: EDIT is currently trading at $2.51, which is considered fair relative to its 30-day fair value range of $2.48 to $2.80.
Technical Outlook: Technically, EDIT is in a strong uptrend. Immediate support is located at $2.25, while resistance sits at $2.97.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.10 (+143.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EDIT is in a strong uptrend. Immediate support is located at $2.25, while resistance sits at $2.97.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.10 (+143.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.48 -
$2.80
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 143.0% below Wall St target ($6.10)
- NEUTRAL: Bottoming setup forming (50/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$2.48 -
$2.80
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.25
Resistance Level
$2.97
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.33
Wall Street Target
$6.10
(+143.0%)
Revenue Growth (YoY)
232.3%
Profit Margin
-157.3%
Share & Embed Analysis
Last updated: October 22, 2026 5:55 AM ET
Data refreshes hourly during market hours. Next update: 6:54 AM
Data refreshes hourly during market hours. Next update: 6:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EDIT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 50 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 47 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 71 BUY |
